Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Clasificación en acciones #24601
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Precio por acción
$3.09
Capitalización bursátil
$58.82M
Cambio (1 día)
0.33%
Cambio (1 año)
-73.01%
País
US
Comercio Elicio Therapeutics, Inc. (ELTX)

Categoría

Historial de desdoblamientos de acciones de Elicio Therapeutics, Inc. (ELTX)
La acción Elicio Therapeutics, Inc. (símbolo: ELTX) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 21, 2026.
Una acción ELTX comprada antes de Aug 21, 2026 equivaldría hoy a 0 acciones ELTX.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH